[{"id":"3d25c448-acf8-4e6b-a932-342422e06f4f","acronym":"","url":"https://clinicaltrials.gov/study/NCT06908304","created_at":"2025-09-07T01:12:54.209Z","updated_at":"2025-09-07T01:12:54.209Z","phase":"Phase 3","brief_title":"A Phase III Study With THIO + Cemiplimab vs Chemotherapy as 3rd Line Treatment in Advanced/Metastatic NSCLC","source_id_and_acronym":"NCT06908304","lead_sponsor":"Maia Biotechnology","biomarkers":" PD-L1","pipe":"","alterations":" ","tags":["PD-L1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e gemcitabine • docetaxel • Libtayo (cemiplimab-rwlc) • vinorelbine tartrate • ateganosine (THIO)"],"overall_status":"Not yet recruiting","enrollment":" Enrollment 300","initiation":"Initiation: 07/28/2025","start_date":" 07/28/2025","primary_txt":" Primary completion: 07/29/2026","primary_completion_date":" 07/29/2026","study_txt":" Completion: 07/29/2027","study_completion_date":" 07/29/2027","last_update_posted":"2025-04-08"},{"id":"74157a34-d6de-4ba9-9962-025f2effcf7f","acronym":"ALPHABET","url":"https://clinicaltrials.gov/study/NCT05063786","created_at":"2021-10-01T11:54:26.039Z","updated_at":"2025-02-25T12:37:59.796Z","phase":"Phase 3","brief_title":"Trastuzumab + Alpelisib +/- Fulvestrant vs Trastuzumab + CT in Patients With PIK3CA Mutated Previously Treated HER2+ Advanced BrEasT Cancer (ALPHABET)","source_id_and_acronym":"NCT05063786 - ALPHABET","lead_sponsor":"Spanish Breast Cancer Research Group","biomarkers":" HER-2 • ER • PIK3CA • PGR","pipe":" | ","alterations":" ER positive • PIK3CA mutation","tags":["HER-2 • ER • PIK3CA • PGR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e ER positive • PIK3CA mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Herceptin (trastuzumab) • capecitabine • Piqray (alpelisib) • fulvestrant • Halaven (eribulin mesylate) • vinorelbine tartrate • Navelbine oral (vinorelbine tartrate oral)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 27","initiation":"Initiation: 09/14/2021","start_date":" 09/14/2021","primary_txt":" Primary completion: 06/01/2025","primary_completion_date":" 06/01/2025","study_txt":" Completion: 06/01/2025","study_completion_date":" 06/01/2025","last_update_posted":"2025-02-24"},{"id":"c5baf3d3-95f8-46cc-89ee-2ac65d9ade70","acronym":"","url":"https://clinicaltrials.gov/study/NCT06023641","created_at":"2023-09-05T18:12:33.949Z","updated_at":"2025-02-25T12:29:46.532Z","phase":"Phase 1/2","brief_title":"Treatment of Newly Diagnosed Rhabdomyosarcoma Using Molecular Risk Stratification and Liposomal Irinotecan Based Therapy in Children With Intermediate and High Risk Disease","source_id_and_acronym":"NCT06023641","lead_sponsor":"St. Jude Children's Research Hospital","biomarkers":" TP53 • FOXO1 • MYOD1","pipe":" | ","alterations":" TP53 mutation","tags":["TP53 • FOXO1 • MYOD1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e TP53 mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e temozolomide • cyclophosphamide • vincristine • vinorelbine tartrate • dactinomycin • Onivyde (nanoliposomal irinotecan) • Navelbine oral (vinorelbine tartrate oral) • Neupogen (filgrastim)"],"overall_status":"Recruiting","enrollment":" Enrollment 100","initiation":"Initiation: 03/13/2024","start_date":" 03/13/2024","primary_txt":" Primary completion: 10/01/2034","primary_completion_date":" 10/01/2034","study_txt":" Completion: 10/01/2037","study_completion_date":" 10/01/2037","last_update_posted":"2025-02-24"},{"id":"2aac339a-fbd4-48aa-9c04-5e7a6adc7234","acronym":"NCI-MATCH","url":"https://clinicaltrials.gov/study/NCT02465060","created_at":"2021-01-17T17:15:30.769Z","updated_at":"2025-02-25T16:36:36.993Z","phase":"Phase 2","brief_title":"Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial)","source_id_and_acronym":"NCT02465060 - NCI-MATCH","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" MSI • CD4","pipe":" | ","alterations":" PD-L1 expression","tags":["MSI • CD4"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e PD-L1 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Keytruda (pembrolizumab) • Opdivo (nivolumab) • Avastin (bevacizumab) • Herceptin (trastuzumab) • Lynparza (olaparib) • Mekinist (trametinib) • cisplatin • Xalkori (crizotinib) • Tagrisso (osimertinib) • Tecentriq (atezolizumab) • Gilotrif (afatinib) • Yervoy (ipilimumab) • Ibrance (palbociclib) • dasatinib • Tafinlar (dabrafenib) • carboplatin • Imfinzi (durvalumab) • Vitrakvi (larotrectinib) • Imbruvica (ibrutinib) • gemcitabine • paclitaxel • Rituxan (rituximab) • docetaxel • 5-fluorouracil • sunitinib • everolimus • Vectibix (panitumumab) • temozolomide • Koselugo (selumetinib) • Perjeta (pertuzumab) • cytarabine • Kadcyla (ado-trastuzumab emtansine) • bortezomib • doxorubicin hydrochloride • Talzenna (talazoparib) • capecitabine • Piqray (alpelisib) • Xtandi (enzalutamide) • azacitidine • Cabometyx (cabozantinib tablet) • Balversa (erdafitinib) • Gazyva (obinutuzumab) • Mektovi (binimetinib) • albumin-bound paclitaxel • cyclophosphamide • Imjudo (tremelimumab-actl) • Cyramza (ramucirumab) • pemetrexed • fulvestrant • oxaliplatin • adavosertib (AZD1775) • etoposide IV • irinotecan • Halaven (eribulin mesylate) • Xpovio (selinexor) • Conmana (icotinib) • Pemazyre (pemigatinib) • Truqap (capivasertib) • methotrexate • Zarnestra (tipifarnib) • Aliqopa (copanlisib) • fexagratinib (ABSK091) • Ninlaro (ixazomib) • pegylated liposomal doxorubicin • epirubicin • sapanisertib (CB-228) • ipatasertib (RG7440) • Caprelsa (vandetanib) • vincristine • vinorelbine tartrate • Cometriq (cabozantinib capsule) • Tabrecta (capmatinib) • spartalizumab (PDR001) • taselisib (GDC-0032) • daunorubicin • omipalisib (GSK2126458) • ulixertinib (BVD-523) • mitoxantrone • Erivedge (vismodegib) • carmustine • bendamustine • bicalutamide • leucovorin calcium • Mvasi (bevacizumab-awwb) • Vegzelma (bevacizumab-adcd) • Zepzelca (lurbinectedin) • mitomycin • Jingzhuda (entinostat) • Recentin (cediranib) • Trazimera (trastuzumab-qyyp) • melphalan • Fakzynja (defactinib) • GSK2636771 • Zirabev (bevacizumab-bvzr) • goserelin acetate • Zynyz (retifanlimab-dlwr) • fludarabine IV • Ostarine (enobosarm) • avadomide (CC-122) • vistusertib (AZD2014) • Myocet (non-pegylated liposomal doxorubicin) • mesna • vinblastine • Xofigo (radium Ra-223 dichloride) • lorvotuzumab mertansine (IMGN901) • Ampligen (rintatolimod) • E6201 • Fujovee (abivertinib) • Paletan (pertuzumab biosimilar) • Provenge (sipuleucel-T) • relatlimab (BMS-986016) • ABP 206 (nivolumab biosimilar) • Airuituo (bevacizumab biosimilar) • Beianting (bevacizumab biosimilar) • Boyounuo (bevacizumab biosimilar) • CC-90002 • EG1206A (pertuzumab biosimilar) • GB222 (bevacizumab biosimilar) • Hanbeitai (bevacizumab biosimilar) • ImmuniCell (autologous γδ T lymphocytes) • Leukine (sargramostim) • Pertuvia (pertuzumab biosimilar) • Vasforda (bevacizumab biosimilar) • celecoxib oral • cyclophosphamide intravenous • dexamethasone injection • ieramilimab (LAG525) • levoleucovorin calcium • methotrexate IV • sapitinib (AZD8931)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 6452","initiation":"Initiation: 08/17/2015","start_date":" 08/17/2015","primary_txt":" Primary completion: 12/31/2025","primary_completion_date":" 12/31/2025","study_txt":" Completion: 12/31/2025","study_completion_date":" 12/31/2025","last_update_posted":"2025-02-06"},{"id":"e6ddbe9a-bb3f-4f95-a33c-1e9db3a4644c","acronym":"ALINA","url":"https://clinicaltrials.gov/study/NCT03456076","created_at":"2021-01-18T17:02:25.362Z","updated_at":"2025-02-25T16:44:20.606Z","phase":"Phase 3","brief_title":"A Study Comparing Adjuvant Alectinib Versus Adjuvant Platinum-Based Chemotherapy in Patients With ALK Positive Non-Small Cell Lung Cancer","source_id_and_acronym":"NCT03456076 - ALINA","lead_sponsor":"Hoffmann-La Roche","biomarkers":" ALK","pipe":" | ","alterations":" ALK positive","tags":["ALK"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e ALK positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cisplatin • carboplatin • gemcitabine • Alecensa (alectinib) • pemetrexed • vinorelbine tartrate"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 257","initiation":"Initiation: 08/16/2018","start_date":" 08/16/2018","primary_txt":" Primary completion: 06/26/2023","primary_completion_date":" 06/26/2023","study_txt":" Completion: 11/19/2026","study_completion_date":" 11/19/2026","last_update_posted":"2025-02-05"},{"id":"d16edb9e-05b0-4a67-8757-e2748c115c02","acronym":"ARST1431","url":"https://clinicaltrials.gov/study/NCT02567435","created_at":"2024-01-09T20:20:40.495Z","updated_at":"2025-02-25T16:51:34.054Z","phase":"Phase 3","brief_title":"Combination Chemotherapy With or Without Temsirolimus in Treating Patients With Intermediate Risk Rhabdomyosarcoma","source_id_and_acronym":"NCT02567435 - ARST1431","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" FOXO1 • PAX3 • PAX7","pipe":"","alterations":" ","tags":["FOXO1 • PAX3 • PAX7"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cyclophosphamide • irinotecan • temsirolimus • vincristine • vinorelbine tartrate • dactinomycin"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 325","initiation":"Initiation: 06/01/2016","start_date":" 06/01/2016","primary_txt":" Primary completion: 06/30/2023","primary_completion_date":" 06/30/2023","study_txt":" Completion: 10/16/2025","study_completion_date":" 10/16/2025","last_update_posted":"2025-02-04"},{"id":"64fbfa8e-e3d5-4527-8e70-e669cf683ef4","acronym":"MOVIE","url":"https://clinicaltrials.gov/study/NCT03518606","created_at":"2021-01-18T17:19:19.354Z","updated_at":"2025-02-25T15:07:35.561Z","phase":"Phase 1/2","brief_title":"Metronomic Oral Vinorelbine Plus Anti-PD-L1/Anti-CTLA4 ImmunothErapy in Patients With Advanced Solid Tumours","source_id_and_acronym":"NCT03518606 - MOVIE","lead_sponsor":"UNICANCER","biomarkers":" TMB","pipe":"","alterations":" ","tags":["TMB"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Imfinzi (durvalumab) • Imjudo (tremelimumab-actl) • vinorelbine tartrate • Navelbine oral (vinorelbine tartrate oral)"],"overall_status":"Completed","enrollment":" Enrollment 126","initiation":"Initiation: 06/20/2018","start_date":" 06/20/2018","primary_txt":" Primary completion: 04/01/2022","primary_completion_date":" 04/01/2022","study_txt":" Completion: 12/19/2024","study_completion_date":" 12/19/2024","last_update_posted":"2025-01-15"},{"id":"a823c207-e7e1-4f29-8a31-680d49989ddd","acronym":"AVIATOR","url":"https://clinicaltrials.gov/study/NCT03414658","created_at":"2021-01-18T16:50:49.598Z","updated_at":"2025-02-25T13:52:30.920Z","phase":"Phase 2","brief_title":"The AVIATOR Study: Trastuzumab and Vinorelbine With Avelumab OR Avelumab \u0026 Utomilumab in Advanced HER2+ Breast Cancer","source_id_and_acronym":"NCT03414658 - AVIATOR","lead_sponsor":"Adrienne G. Waks","biomarkers":" HER-2 • PD-L1","pipe":" | ","alterations":" HER-2 positive • HER-2 amplification","tags":["HER-2 • PD-L1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HER-2 positive • HER-2 amplification"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Herceptin (trastuzumab) • Perjeta (pertuzumab) • Bavencio (avelumab) • vinorelbine tartrate • utomilumab (PF-05082566)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 100","initiation":"Initiation: 06/21/2018","start_date":" 06/21/2018","primary_txt":" Primary completion: 05/01/2023","primary_completion_date":" 05/01/2023","study_txt":" Completion: 05/31/2025","study_completion_date":" 05/31/2025","last_update_posted":"2024-11-06"},{"id":"0d569526-0a1b-477a-bbb0-9fbb8b295214","acronym":"ARCADIAN","url":"https://clinicaltrials.gov/study/NCT04648033","created_at":"2021-01-19T20:40:00.018Z","updated_at":"2024-07-02T16:34:25.606Z","phase":"Phase 1","brief_title":"Atovaquone With Radical ChemorADIotherapy in Locally Advanced NSCLC","source_id_and_acronym":"NCT04648033 - ARCADIAN","lead_sponsor":"University of Oxford","biomarkers":" MIR210","pipe":"","alterations":" ","tags":["MIR210"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cisplatin • vinorelbine tartrate • atovaquone"],"overall_status":"Completed","enrollment":" Enrollment 21","initiation":"Initiation: 12/07/2020","start_date":" 12/07/2020","primary_txt":" Primary completion: 10/02/2023","primary_completion_date":" 10/02/2023","study_txt":" Completion: 10/02/2023","study_completion_date":" 10/02/2023","last_update_posted":"2024-06-17"},{"id":"1c9daf03-acbe-412b-99d6-f63aac6d1d20","acronym":"EVER-132-002","url":"https://clinicaltrials.gov/study/NCT04639986","created_at":"2021-01-19T20:38:27.058Z","updated_at":"2024-07-02T16:34:26.121Z","phase":"Phase 3","brief_title":"Asian Study of Sacituzumab Govitecan (IMMU-132) in HR+/HER2- Metastatic Breast Cancer (MBC)","source_id_and_acronym":"NCT04639986 - EVER-132-002","lead_sponsor":"Gilead Sciences","biomarkers":" HER-2","pipe":" | ","alterations":" HER-2 positive • HR positive • HER-2 negative • HR positive + HER-2 negative","tags":["HER-2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HER-2 positive • HR positive • HER-2 negative • HR positive + HER-2 negative"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e gemcitabine • capecitabine • Halaven (eribulin mesylate) • vinorelbine tartrate • Trodelvy (sacituzumab govitecan-hziy)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 331","initiation":"Initiation: 11/23/2020","start_date":" 11/23/2020","primary_txt":" Primary completion: 12/01/2025","primary_completion_date":" 12/01/2025","study_txt":" Completion: 12/01/2025","study_completion_date":" 12/01/2025","last_update_posted":"2024-06-14"},{"id":"43fbfbcb-f326-4024-95a0-b6bf5afd97c2","acronym":"DETECT V","url":"https://clinicaltrials.gov/study/NCT02344472","created_at":"2021-01-18T11:08:55.334Z","updated_at":"2025-02-25T13:34:30.541Z","phase":"Phase 3","brief_title":"Detect V / CHEVENDO (Chemo vs. Endo)","source_id_and_acronym":"NCT02344472 - DETECT V","lead_sponsor":"Prof. Wolfgang Janni","biomarkers":" HER-2","pipe":" | ","alterations":" HER-2 positive • HR positive","tags":["HER-2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HER-2 positive • HR positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Herceptin (trastuzumab) • docetaxel • Perjeta (pertuzumab) • capecitabine • albumin-bound paclitaxel • Kisqali (ribociclib) • fulvestrant • Halaven (eribulin mesylate) • letrozole • vinorelbine tartrate • anastrozole • exemestane • goserelin acetate • leuprolide acetate for depot suspension"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 271","initiation":"Initiation: 09/01/2015","start_date":" 09/01/2015","primary_txt":" Primary completion: 01/31/2025","primary_completion_date":" 01/31/2025","study_txt":" Completion: 01/31/2025","study_completion_date":" 01/31/2025","last_update_posted":"2024-06-04"},{"id":"8c8ff781-f391-42de-9882-e4814d7bf8ab","acronym":"","url":"https://clinicaltrials.gov/study/NCT03887130","created_at":"2021-01-18T19:09:12.750Z","updated_at":"2024-07-02T16:35:07.040Z","phase":"Phase 2","brief_title":"Study of Oral Vinorelbine Plus Capecitabine Versus Taxane-gemcitabine Combinations as 1st Line Chemotherapy in Metastatic Breast Cancer","source_id_and_acronym":"NCT03887130","lead_sponsor":"Pierre Fabre Medicament","biomarkers":" HER-2","pipe":" | ","alterations":" HER-2 negative","tags":["HER-2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HER-2 negative"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e gemcitabine • paclitaxel • docetaxel • capecitabine • vinorelbine tartrate • Navelbine oral (vinorelbine tartrate oral)"],"overall_status":"Completed","enrollment":" Enrollment 152","initiation":"Initiation: 03/27/2007","start_date":" 03/27/2007","primary_txt":" Primary completion: 04/18/2013","primary_completion_date":" 04/18/2013","study_txt":" Completion: 04/18/2013","study_completion_date":" 04/18/2013","last_update_posted":"2024-04-30"},{"id":"cacc6ec6-cc9c-4631-96db-9a1cadb66db9","acronym":"TROPION-Breast01","url":"https://clinicaltrials.gov/study/NCT05104866","created_at":"2021-11-03T13:53:11.926Z","updated_at":"2024-07-02T16:35:08.148Z","phase":"Phase 3","brief_title":"A Phase-3, Open-Label, Randomized Study of Dato-DXd Versus Investigator's Choice of Chemotherapy (ICC) in Participants With Inoperable or Metastatic HR-Positive, HER2-Negative Breast Cancer Who Have Been Treated With One or Two Prior Lines of Systemic Chemotherapy (TROPION-Breast01)","source_id_and_acronym":"NCT05104866 - TROPION-Breast01","lead_sponsor":"AstraZeneca","biomarkers":" HER-2","pipe":" | ","alterations":" HER-2 negative","tags":["HER-2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HER-2 negative"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e gemcitabine • capecitabine • Halaven (eribulin mesylate) • vinorelbine tartrate • Datroway (datopotamab deruxtecan-dlnk)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 732","initiation":"Initiation: 10/18/2021","start_date":" 10/18/2021","primary_txt":" Primary completion: 08/15/2025","primary_completion_date":" 08/15/2025","study_txt":" Completion: 08/15/2025","study_completion_date":" 08/15/2025","last_update_posted":"2024-04-23"},{"id":"f2b35136-f790-410c-b54a-4f61af16101b","acronym":"ZWI-ZW25-101","url":"https://clinicaltrials.gov/study/NCT02892123","created_at":"2021-01-17T17:13:28.525Z","updated_at":"2024-07-02T16:35:08.789Z","phase":"Phase 1","brief_title":"Trial of ZW25 (Zanidatamab) in Patients With Advanced HER2-expressing Cancers","source_id_and_acronym":"NCT02892123 - ZWI-ZW25-101","lead_sponsor":"Jazz Pharmaceuticals","biomarkers":" EGFR • HER-2 • KRAS • ALK • ROS1","pipe":" | ","alterations":" HER-2 positive • HER-2 overexpression • EGFR wild-type • KRAS wild-type • ALK wild-type • RAS wild-type • EGFR wild-type + ALK wild-type • ALK-ROS1 fusion","tags":["EGFR • HER-2 • KRAS • ALK • ROS1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HER-2 positive • HER-2 overexpression • EGFR wild-type • KRAS wild-type • ALK wild-type • RAS wild-type • EGFR wild-type + ALK wild-type • ALK-ROS1 fusion"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e paclitaxel • capecitabine • Tukysa (tucatinib) • vinorelbine tartrate • Ziihera (zanidatamab-hrii)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 279","initiation":"Initiation: 09/30/2016","start_date":" 09/30/2016","primary_txt":" Primary completion: 06/01/2024","primary_completion_date":" 06/01/2024","study_txt":" Completion: 07/01/2024","study_completion_date":" 07/01/2024","last_update_posted":"2024-04-18"},{"id":"afe43d49-149b-4cfa-8b78-6654142743ad","acronym":"VIGOR","url":"https://clinicaltrials.gov/study/NCT05583188","created_at":"2022-10-17T13:56:08.403Z","updated_at":"2024-07-02T16:35:14.942Z","phase":"Phase 4","brief_title":"Neoadjuvant Aliya™ PEF Soft Tissue Ablation With Systemic Therapy in Early-Stage Resectable NSCLC","source_id_and_acronym":"NCT05583188 - VIGOR","lead_sponsor":"Galvanize Therapeutics, Inc.","biomarkers":" EGFR • ALK","pipe":" | ","alterations":" EGFR mutation • ALK mutation","tags":["EGFR • ALK"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e EGFR mutation • ALK mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Opdivo (nivolumab) • cisplatin • carboplatin • gemcitabine • paclitaxel • docetaxel • pemetrexed • vinorelbine tartrate"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 15","initiation":"Initiation: 02/01/2023","start_date":" 02/01/2023","primary_txt":" Primary completion: 06/30/2024","primary_completion_date":" 06/30/2024","study_txt":" Completion: 06/30/2024","study_completion_date":" 06/30/2024","last_update_posted":"2024-03-13"},{"id":"94f2c520-fdab-4936-980c-693760a72522","acronym":"METEORA-II","url":"https://clinicaltrials.gov/study/NCT02954055","created_at":"2021-01-18T14:30:32.840Z","updated_at":"2024-07-02T16:35:17.646Z","phase":"Phase 2","brief_title":"MEtronomic TrEatment Option in Advanced bReast cAncer","source_id_and_acronym":"NCT02954055 - METEORA-II","lead_sponsor":"ETOP IBCSG Partners Foundation","biomarkers":" HER-2 • ER","pipe":" | ","alterations":" ER positive • HER-2 negative","tags":["HER-2 • ER"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e ER positive • HER-2 negative"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e paclitaxel • capecitabine • cyclophosphamide • vinorelbine tartrate • Navelbine oral (vinorelbine tartrate oral) • cyclophosphamide intravenous"],"overall_status":"Completed","enrollment":" Enrollment 140","initiation":"Initiation: 09/13/2017","start_date":" 09/13/2017","primary_txt":" Primary completion: 11/17/2021","primary_completion_date":" 11/17/2021","study_txt":" Completion: 11/23/2022","study_completion_date":" 11/23/2022","last_update_posted":"2024-02-26"},{"id":"23e2bcb5-1612-4e8c-afcb-bd63c8997ee0","acronym":"","url":"https://clinicaltrials.gov/study/NCT04388839","created_at":"2023-08-27T06:10:27.849Z","updated_at":"2024-07-02T16:35:18.394Z","phase":"Phase 2","brief_title":"Evolutionary Therapy for Rhabdomyosarcoma","source_id_and_acronym":"NCT04388839","lead_sponsor":"H. Lee Moffitt Cancer Center and Research Institute","biomarkers":" FOXO1","pipe":"","alterations":" ","tags":["FOXO1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e doxorubicin hydrochloride • cyclophosphamide • irinotecan • vincristine • vinorelbine tartrate • dactinomycin • Navelbine oral (vinorelbine tartrate oral)"],"overall_status":"Recruiting","enrollment":" Enrollment 28","initiation":"Initiation: 09/27/2020","start_date":" 09/27/2020","primary_txt":" Primary completion: 12/01/2026","primary_completion_date":" 12/01/2026","study_txt":" Completion: 12/01/2027","study_completion_date":" 12/01/2027","last_update_posted":"2024-02-21"},{"id":"f12a9fa2-bed6-4d25-ae61-5404aaa84b45","acronym":"BCTOP-T-M01","url":"https://clinicaltrials.gov/study/NCT05806060","created_at":"2023-04-10T14:03:10.896Z","updated_at":"2024-07-02T16:35:20.214Z","phase":"Phase 3","brief_title":"Precise Treatment for BLIS Subtype of TNBC in the First-line Treatment of Locally Advanced or Metastatic Breast Cancer","source_id_and_acronym":"NCT05806060 - BCTOP-T-M01","lead_sponsor":"Fudan University","biomarkers":" HER-2","pipe":" | ","alterations":" HER-2 expression • PGR expression","tags":["HER-2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HER-2 expression • PGR expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Avastin (bevacizumab) • carboplatin • capecitabine • albumin-bound paclitaxel • Halaven (eribulin mesylate) • vinorelbine tartrate"],"overall_status":"Recruiting","enrollment":" Enrollment 192","initiation":"Initiation: 04/25/2023","start_date":" 04/25/2023","primary_txt":" Primary completion: 08/31/2025","primary_completion_date":" 08/31/2025","study_txt":" Completion: 02/28/2026","study_completion_date":" 02/28/2026","last_update_posted":"2024-02-08"},{"id":"1d2920ad-7680-4e69-b51f-ddb29e043f61","acronym":"ACT","url":"https://clinicaltrials.gov/study/NCT05238831","created_at":"2023-08-08T16:08:43.868Z","updated_at":"2025-02-25T12:28:40.109Z","phase":"Phase 1","brief_title":"SMMART Adaptive Clinical Treatment (ACT) Trial","source_id_and_acronym":"NCT05238831 - ACT","lead_sponsor":"OHSU Knight Cancer Institute","biomarkers":" HER-2 • BRCA1 • BRCA2","pipe":" | ","alterations":" HR positive • HER-2 negative • EGFR positive","tags":["HER-2 • BRCA1 • BRCA2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HR positive • HER-2 negative • EGFR positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Avastin (bevacizumab) • Herceptin (trastuzumab) • Lynparza (olaparib) • Tecentriq (atezolizumab) • Ibrance (palbociclib) • Zelboraf (vemurafenib) • carboplatin • Rozlytrek (entrectinib) • Alecensa (alectinib) • Kadcyla (ado-trastuzumab emtansine) • Cotellic (cobimetinib) • capecitabine • Piqray (alpelisib) • Zejula (niraparib) • albumin-bound paclitaxel • fulvestrant • irinotecan • Halaven (eribulin mesylate) • letrozole • vinorelbine tartrate • Herzuma (trastuzumab-pkrb) • anastrozole • Erivedge (vismodegib) • Trazimera (trastuzumab-qyyp) • Phesgo (pertuzumab/trastuzumab/hyaluronidase-zzxf) • EG1206A (pertuzumab biosimilar)"],"overall_status":"Withdrawn","enrollment":"","initiation":"Initiation: 01/30/2023","start_date":" 01/30/2023","primary_txt":" Primary completion: 05/31/2026","primary_completion_date":" 05/31/2026","study_txt":" Completion: 05/31/2026","study_completion_date":" 05/31/2026","last_update_posted":"2024-01-23"},{"id":"d706a100-20c3-4942-98f1-dac486c56909","acronym":"ORIENTA","url":"https://clinicaltrials.gov/study/NCT06102824","created_at":"2023-10-26T15:14:20.313Z","updated_at":"2024-07-02T16:35:23.595Z","phase":"Phase 2","brief_title":"Organoid-based Functional Precision Therapy for Advanced Breast Cancer","source_id_and_acronym":"NCT06102824 - ORIENTA","lead_sponsor":"Guangdong Provincial People's Hospital","biomarkers":" HER-2 • ER • PGR","pipe":" | ","alterations":" HR positive • HER-2 negative • ER positive + PGR positive","tags":["HER-2 • ER • PGR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HR positive • HER-2 negative • ER positive + PGR positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e carboplatin • gemcitabine • Enhertu (fam-trastuzumab deruxtecan-nxki) • capecitabine • albumin-bound paclitaxel • cyclophosphamide • Halaven (eribulin mesylate) • pegylated liposomal doxorubicin • vinorelbine tartrate • Trodelvy (sacituzumab govitecan-hziy) • Ixempra (ixabepilone) • Lipusu (liposomal paclitaxel) • utidelone IV (UTD1)"],"overall_status":"Recruiting","enrollment":" Enrollment 252","initiation":"Initiation: 01/20/2024","start_date":" 01/20/2024","primary_txt":" Primary completion: 06/30/2027","primary_completion_date":" 06/30/2027","study_txt":" Completion: 06/30/2028","study_completion_date":" 06/30/2028","last_update_posted":"2024-01-12"},{"id":"7e9c533e-cc6e-4694-9c54-aa34b9f00feb","acronym":"TROPiCS-02","url":"https://clinicaltrials.gov/study/NCT03901339","created_at":"2021-01-17T17:20:16.035Z","updated_at":"2024-07-02T16:35:28.572Z","phase":"Phase 3","brief_title":"Study of Sacituzumab Govitecan-hziy Versus Treatment of Physician's Choice in Participants With HR+/HER2- Metastatic Breast Cancer","source_id_and_acronym":"NCT03901339 - TROPiCS-02","lead_sponsor":"Gilead Sciences","biomarkers":" HER-2","pipe":" | ","alterations":" HR positive • HER-2 negative • EGFR positive","tags":["HER-2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HR positive • HER-2 negative • EGFR positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e gemcitabine • capecitabine • Halaven (eribulin mesylate) • vinorelbine tartrate • Trodelvy (sacituzumab govitecan-hziy)"],"overall_status":"Completed","enrollment":" Enrollment 543","initiation":"Initiation: 05/08/2019","start_date":" 05/08/2019","primary_txt":" Primary completion: 10/20/2023","primary_completion_date":" 10/20/2023","study_txt":" Completion: 10/20/2023","study_completion_date":" 10/20/2023","last_update_posted":"2023-11-20"},{"id":"9bb7bb9e-db75-4fab-bcdd-b2ad20ffdc3a","acronym":"","url":"https://clinicaltrials.gov/study/NCT06107790","created_at":"2023-10-30T16:12:59.603Z","updated_at":"2024-07-02T16:35:31.287Z","phase":"Phase 3","brief_title":"Phase III Clinical Trial Comparing the Safety, Efficacy, and Immunogenicity of HS022 and Trastuzumab® in Combination With Vinorelbine Bitartrate Injection in the Treatment of HER2-positive Breast Cancer","source_id_and_acronym":"NCT06107790","lead_sponsor":"Zhejiang Hisun Pharmaceutical Co. Ltd.","biomarkers":" HER-2","pipe":" | ","alterations":" HER-2 positive • HER-2 amplification","tags":["HER-2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HER-2 positive • HER-2 amplification"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Herceptin (trastuzumab) • vinorelbine tartrate"],"overall_status":"Completed","enrollment":" Enrollment 570","initiation":"Initiation: 05/16/2018","start_date":" 05/16/2018","primary_txt":" Primary completion: 01/28/2022","primary_completion_date":" 01/28/2022","study_txt":" Completion: 01/28/2022","study_completion_date":" 01/28/2022","last_update_posted":"2023-10-30"},{"id":"a544e8bf-0923-4309-b003-451edd56ff00","acronym":"","url":"https://clinicaltrials.gov/study/NCT05347134","created_at":"2022-04-26T13:53:52.328Z","updated_at":"2024-07-02T16:35:32.427Z","phase":"Phase 3","brief_title":"SKB264 Injection vs Investigator Selected Regimens to Treat Locally Advanced, Recurrent or Metastatic Triple-negative Breast Cancer","source_id_and_acronym":"NCT05347134","lead_sponsor":"Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.","biomarkers":" HER-2 • PGR • BRCA1 • BRCA2","pipe":" | ","alterations":" BRCA2 mutation • BRCA1 mutation • HER-2 negative • HER-2 expression • PGR negative","tags":["HER-2 • PGR • BRCA1 • BRCA2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e BRCA2 mutation • BRCA1 mutation • HER-2 negative • HER-2 expression • PGR negative"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e gemcitabine • capecitabine • Halaven (eribulin mesylate) • vinorelbine tartrate • Jiataile (sacituzumab tirumotecan)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 254","initiation":"Initiation: 06/10/2022","start_date":" 06/10/2022","primary_txt":" Primary completion: 10/31/2023","primary_completion_date":" 10/31/2023","study_txt":" Completion: 12/31/2024","study_completion_date":" 12/31/2024","last_update_posted":"2023-10-20"},{"id":"8fafd500-cd59-43ea-9e23-43590458cf10","acronym":"BRIDGE","url":"https://clinicaltrials.gov/study/NCT04765709","created_at":"2021-02-21T12:52:31.220Z","updated_at":"2025-02-25T14:59:44.428Z","phase":"Phase 2","brief_title":"Durvalumab and Chemotherapy Induction Followed by Durvalumab and Radiotherapy in Large Volume Stage III NSCLC","source_id_and_acronym":"NCT04765709 - BRIDGE","lead_sponsor":"Mario Negri Institute for Pharmacological Research","biomarkers":" PD-L1","pipe":"","alterations":" ","tags":["PD-L1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cisplatin • carboplatin • Imfinzi (durvalumab) • pemetrexed • vinorelbine tartrate"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 10","initiation":"Initiation: 09/24/2021","start_date":" 09/24/2021","primary_txt":" Primary completion: 06/01/2026","primary_completion_date":" 06/01/2026","study_txt":" Completion: 06/01/2026","study_completion_date":" 06/01/2026","last_update_posted":"2023-10-19"}]